Contraceptive shortage blamed on takeover; WHO struggles to form fakes-policy group;

> Contraceptives maker MSD, the U.K. arm of Merck, has reportedly blamed the shortage of its Cerazette, Marvelon and Mercilon brands on its takeover of rival Schering-Plough in 2009. Article

> A working group mandated last May by WHO to address problems with counterfeits policy remains unformed just four months before it is due to report to members. Article

> Perrigo will acquire generics-maker Paddock Laboratories for $540 million. Release

> Boehringer Ingelheim will take over Amgen's 100,000-square-foot manufacturing facility with pilot plant and process development labs in Fremont, CA. Release

> Molecular Profiles is expanding its manufacturing services to encompass preformulation through  Phase 2a trials. Item

> Rentschler Biotechnologie is expected to assume manufacturing responsibility for lung injury treatment Traumakine and a proprietary bulk drug product. Item

> Cambrex has received manufacturing approval from the Danish Medicines Agency for its plan t in Hyderabad, India. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.